Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial

Abstract Background Due to the lack of effective treatment options, the prognosis of patients with relapsed/refractory acute myeloid leukemia (R/R AML) remains poor. Although chimeric antigen receptor (CAR)-T-cell therapy has shown promising effects in acute lymphoblastic leukemia (ALL) and lymphoma...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Ruihao Huang, Xiaoqi Wang, Hongju Yan, Xu Tan, Yingying Ma, Maihong Wang, Xiao Han, Jia Liu, Li Gao, Lei Gao, Guangjun Jing, Cheng Zhang, Qin Wen, Xi Zhang
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2025-01-01
Ráidu:	Experimental Hematology & Oncology
Fáttát:	CAR-NK R/R AML CD33
Liŋkkat:	https://doi.org/10.1186/s40164-024-00592-6
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!